Marco Ruella, MD
Assistant Professor of Medicine (Hematology-Oncology)
Project Member, Parker Institute for Cancer Immunotherapy
Leader, Cancer Research, Institute for Immunology
Scientific Director, Lymphoma Program, Division of Hematology and Oncology
Full Member, Abramson Cancer Center, Immunobiology Program
Department: Medicine
Graduate Group Affiliations
Contact information
South Tower 8-112
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 191004
Office: 215-746-4880
Fax: 215-573-3638
Lab: 215-573-8538
Fax: 215-573-3638
Lab: 215-573-8538
Email:
mruella@upenn.edu
mruella@upenn.edu
Publications
Links
Search PubMed for articles
Academia.edu
Google Scholar
Research Gate
Twitter
Ruella Lab Website
Institute for Immunology
LinkedIn
Search PubMed for articles
Academia.edu
Google Scholar
Research Gate
Ruella Lab Website
Institute for Immunology
Education:
MD (Medical Degree)
University of Torino, Italy , 2007.
Permanent linkMD (Medical Degree)
University of Torino, Italy , 2007.
Description of Clinical Expertise
Dr. Ruella treat patients affected by hematological cancers and specializes in immunotherapy approaches.Description of Research Expertise
Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.Dr. Marco Ruella obtained his medical degree with high honors and completed his specialization in clinical hematology at the University of Torino, Italy. He was attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was an Instructor at the Biotechnology School at the University of Torino. From late 2012, he was a Post-doctoral Fellow, and then an Instructor at the University of Pennsylvania in the Center for Cellular immunotherapies (Drs. June and Gill). From 2017 to 2018 he served as Associate Director of Dr. June’s laboratory. In 2018, Dr. Ruella was appointed Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Dr. Ruella was awarded many awards and honors, including the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017), the Cancer Support Community Award (2018), the 2018 ASH Joanne Levy, MD, Memorial Award for Outstanding Achievement, the Gilead Sciences Research Scholar in Hematology/Oncology and the Gabrielle’s Angel Foundation Award (2020), and the Leukemia and Lymphoma Society, Translational Research Program (2021). Dr. Ruella is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CART therapy and the Scientific Founder of viTToria biotherapeutics.
Selected Publications
Zhang, Y, Kim KH, Yoon DH, Patel, R.P., Jo JC, Cho H, Lee JH, Lee HJ, Cui LG, Hwang IS, Lee YH, Kim JH, Lee YG, Guruprasad P, Lee JS, Chung J, Ruella M: CT130/18 An open label, does escalation, phase 1 study of AT101, a novel CD10-directed CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma. AACR Annual Meeting 2023.Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, Haug-Kroeper M, Doray B, Gill S, Ruella M, Hayer KE, Weitzman MD, Green AM, Fluhrer R, Singh N.: Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat Commun. 11(13(1)): 3367, June 2022
Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni, K, Ghilrardi G, Lee, YG, Frey N, Scholler J, Gabunia K, Wu G, Chong, E, Porter, D.L., June, C, Schuster S.J., Bhoj, V, Facciabene, A: Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects. Journal for Immunotherapy of Cancer (JITC) 10, November 2022.
Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T cell Immunotherapy against Cancer. Cancer Discov Jul 2022.
Ghilardi G, Chong EA, Svoboda J, Wohlfarth P, Nasta SD, Williamson S, Landsburg JD, Gerson JN, Barta SK, Pajarillo R, Myers J, Chen AI, Schachter L, Yelton R, Ballard HJ, Hodges Dwinal A, Gier S, Victoriano D, Weber E, Napier E, Garfall A, Porter DL, Jäger U, Maziarz RT, Ruella M*, Schuster SJ*. : Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas. Ann Oncol June 2022.
Aznar M.A., Good C.R., Kuramitsu S, Samareh P, AgarwaL S, Donahue G, Ishiyama K, Wellhausen N, Rennels A.K., Ma Y, Tian L, Guedan S, Alexander K.A., Zhang Z, Rommel P.C., Singh N, Glastad K.M., Richardson M.W., Watanabe K, Tanyi J.L., O’Hara M.H., Ruella M, Lacey S.F., Moon E.K., Schuster S.J., Albelda S.M., Lanier L.L., Young R.M., Berger S.L., June C.H.: Mechanisms of CAR T cell dysfunction and identification of transcription factors that drive the exhaustion phenotype. Cancer Research. AACR, 82, June 2022.
Ascierto PA, Avallone A, Bhardwaj N, Bifulco C, Bracarda S, Brody JD, Buonaguro L, Demaria S, Emens LA, Ferris RL, Galon J, Khleif SN, Klebanoff CA, Laskowski T, Melero I, Paulos CM, Pignata S, Ruella M, Svane IM, Taube JM, Fox BA, Hwu P, Puzanov I. : Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd. J Transl Med June 2022.
Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M.: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med 28(4): 713-723, April 2022.
Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, Barta SK, Chong EA, Frey NV, Gerson JN, Landsburg DJ, Ruella M, Schuster SJ, Svoboda J, Weber E, Porter DL.: Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. Clin Lymphoma Myeloma Leuk. 8: e730-e737, Apri 2022.
46. Gill SI, Frey NV, Hexner E, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon A, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov MA, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Blood Adv. 2022 Mar 29:bloodadvances.2022007317. doi: 10.1182/bloodadvances.2022007317. Epub ahead of print. PMID: 35349631.: Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. Blood Advances 8(6(21)): 5774-5785, 2022.